✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Plinabulin is an investigational drug.
There have been 10 clinical trials for Plinabulin. The most recent clinical trial was a Phase 3 trial, which was initiated on May 29th 2018.
The most common disease conditions in clinical trials are Lung Neoplasms, Neutropenia, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are BeyondSpring Pharmaceuticals Inc., Lyudmila Bazhenova, M.D., and National Cancer Institute (NCI).
There are thirty-seven US patents protecting this investigational drug and two hundred and eighty-seven international patents.
Recent Clinical Trials for Plinabulin
|Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)||BeyondSpring Pharmaceuticals Inc.||Phase 2|
|Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)||Memorial Sloan Kettering Cancer Center||Phase 2|
|Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies||M.D. Anderson Cancer Center||Phase 1/Phase 2|
Top disease conditions for Plinabulin
Top clinical trial sponsors for Plinabulin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Plinabulin||See Plans and Pricing||Method of treating a brain tumor||BeyondSpring Pharmaceuticals, Inc. (New York, NY)||See Plans and Pricing|
|Plinabulin||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Plinabulin||See Plans and Pricing||Nanoparticle formulations for delivering multiple therapeutic agents||AMRITA VISHWA VIDYAPEETHAM (Kochi, Kerala, unknown)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Plinabulin||Australia||AU2016229295||2035-03-06||See Plans and Pricing|
|Plinabulin||Australia||AU2021254549||2035-03-06||See Plans and Pricing|
|Plinabulin||Brazil||BR112017018964||2035-03-06||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|